



## **New Product Launch in Hong Kong - HIBOR<sup>®</sup> (Bemiparin Sodium)**

(Hong Kong, 20 December 2005) - Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the Company has been issued with a permit authorizing HIBOR<sup>®</sup> 2500IU, 3500IU, 5000IU, 7500IU and 10000IU to be marketed for use within Hong Kong.

In October 2004, Leespharm announced the Group has signed exclusive distribution agreement with Phivor Pharmaceutical Research S.L. (a Spanish pharmaceutical company) for Hibor<sup>®</sup>, an injectable low molecular weight heparin (Bemiparin Sodium) in pre-filled syringe form for China and Hong Kong market. After the many months of work between Leespharm and Phivor, the Group has successfully received approval from the Department of Health of Hong Kong ("DoH") for its application of registration for this new chemical entity.

Bemiparin sodium is a new second-generation low molecular weight heparin (LMWH) which has shown efficacy in a small number of well controlled trials in the prevention of postoperative VTE in low to moderate and high-risk patients and in the treatment of established DVT. Bemiparin has the lowest mean molecular weight (3600 Da), the longest half-life (5.3 h) and the largest antifactor Xa:antifactor IIa ratio (8:1) of all LMWHs. Bemiparin promotes a greater release of tissue factor pathway inhibitor than unfractionated heparin (UFH) or dalteparin. These properties could result in a more favourable efficacy/safety ratio for bemiparin than for the currently marketed LMWHs. In the meantime, available data suggest that Bemiparin is an effective and useful addition to the available range of LMWHs for the prevention of VTE and treatment of DVT and may have a better safety profile than the ones existed in the market. The product has been registered and marketed in over 30 countries, including UK, Italy, Spain, Austria and Greece.

The two companies are now working closely to prepare for market launch in the Hong Kong. "Phivor will enhance our portfolio in the HK and strengthen the market position of Leespharm," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "This new product launch represents an extraordinary opportunity for consumers and for both companies. We believe that with our keen market knowledge of LMWH in China market, the launch of Hibor<sup>®</sup> in Hong Kong would allow the company to further penetration of this growing market category."

### About Phivor

Phivor is a Spanish pharmaceutical company with a history of over 50 years. It involves scientific research of the highest level in Spain for many years, comparable with developments in the field taking phase in the most advanced countries in the world.

About Lee's

Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*